实用医学杂志 ›› 2025, Vol. 41 ›› Issue (3): 391-395.doi: 10.3969/j.issn.1006-5725.2025.03.013

• 药物与临床 • 上一篇    

星状神经节阻滞联合右美托咪定经鼻喷雾治疗对失眠患者的疗效

黄梓琪1,范晓敏2,刘芳2,林宝佳2,胡顺晴2,刘湘钰2,王双瑞1,王勇佳1,张新建1,2()   

  1. 1.广州中医药大学第三临床医学院 (广东 广州 510405 )
    2.广州中医药大学第三附属医院麻醉科 (广东 广州 510378 )
  • 收稿日期:2024-11-08 出版日期:2025-02-10 发布日期:2025-02-19
  • 通讯作者: 张新建 E-mail:mzkzxj@163.com
  • 基金资助:
    广东省医学科学技术研究基金项目(A2024696);广东省颐养健康慈善基金会资助项目(2024038)

Clinical efficacy of stellate ganglion block combined with intranasal dexmedetomidine spray in patients with insomnia disorders

Ziqi HUANG1,Xiaomin FAN2,Fang LIU2,Baojia LIN2,Shunqing HU2,Xiangyu LIU2,Shuangrui WANG1,Yongjia WANG1,Xinjian. ZHANG1,2()   

  1. *.The Third Clinical Medical College of Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong,China
  • Received:2024-11-08 Online:2025-02-10 Published:2025-02-19
  • Contact: Xinjian. ZHANG E-mail:mzkzxj@163.com

摘要:

目的 评价星状神经节阻滞(SGB)联合右美托咪定经鼻喷雾治疗对失眠患者的疗效。 方法 选取18 ~ 75岁失眠患者64例,随机分为实验组(DS组)和对照组(S组),S组连续14 d进行SGB术,DS组在此基础上于第1 ~ 6天睡前30 min经鼻喷雾给予100 μg右美托咪定,观察并记录两组患者治疗前(T1)、治疗后次日(T2)以及治疗后1个月(T3)匹兹堡睡眠质量指数(PSQI)、抑郁自评量表(SAS)、焦虑自评量表(SDS)评分和心理运动警觉性测试(PVT)结果。 结果 组内比较:DS组和S组在T2和T3时的PSQI评分与各维度分值显著低于T1时(P < 0.05)。DS组和S组的SAS和SDS评分在T3时与T1、T2时相比显著降低(P < 0.05),而PVT结果无显著变化(P > 0.05)。组间比较:DS组在T2(8.44 ± 2.99)和T3(8.22 ± 2.60)时的PSQI评分与各维度分值均显著低于S组在T2(10.88 ± 2.56)和T3(10.88 ± 2.84)时的PSQI评分与各维度分值(P < 0.05),DS组和S组的SDS和SAS评分在T2、T3时相比无显著变化(P > 0.05)。 结论 星状神经节阻滞联合右美托咪定经鼻喷雾治疗与单独SGB术相比,能够显著改善失眠患者的睡眠质量,而对其焦虑抑郁情绪及精神警觉性的影响无明显差异。

关键词: 星状神经节阻滞, 右美托咪定经鼻喷雾, 失眠

Abstract:

Objective To evaluate the clinical efficacy of stellate ganglion block (SGB) combined with intranasal dexmedetomidine for the treatment of insomnia. Methods A total of 64 patients aged 18 to 75 with insomnia were randomly assigned to either the experimental group (DS group) or the control group (S group). The S group received SGB treatment for 14 consecutive days, whereas the DS group received an additional intranasal dexmedetomidine spray at a dose of 100 μg, administered 30 minutes before bedtime on days 1 through 6, in conjunction with SGB. We measured and recorded the Pittsburgh Sleep Quality Index (PSQI), Self?Rating Depression Scale (SDS), Self?Rating Anxiety Scale (SAS) scores, and Psychomotor Vigilance Test (PVT) results for both groups at three time points: baseline (T1), the day after treatment (T2), and one month after treatment (T3). Results Intra?group Comparison: In both the DS and S groups, PSQI scores and dimensionspecific scores at T2 and T3 were significantly lower compared to T1P < 0.05). SAS and SDS scores in both groups showed a significant reduction at T3 compared to T1 and T2P < 0.05), while PVT results exhibited no significant changes(P > 0.05). Inter?group Comparison: The PSQI scores and dimensionspecific scores in the DS group at T2 (8.44 ± 2.99) and T3 (8.22 ± 2.60) were significantly lower than those in the S group at T2 (10.88 ± 2.56) and T3(10.88 ± 2.84) (P < 0.05). However, no significant differences were observed in SDS and SAS scores between the DS and S groups at T2 and T3P > 0.05). Conclusion Compared to standalone SGB, the combination of SGB with intranasal dexmedetomidine significantly enhances sleep quality in patients with insomnia, while not impacting their levels of anxiety, depression, or alertness.

Key words: stellate ganglion block, intranasal dexmedetomidine spray, insomnia disorders

中图分类号: